摘要
本文通过回顾罗非昔布导致心脑血管疾病发生率增加而被召回这一事件 ,提出现有上市后药物安全性监测的问题和对策。
This article aims to review the recall of refecoxib which increases the incidence of cardiovascular and cerebrovascular diseases and to find the methods to solve problems in post marked monitoring of drug safety.
出处
《中国循证医学杂志》
CSCD
2005年第2期94-96,共3页
Chinese Journal of Evidence-based Medicine